Patents by Inventor Nathan Elliott
Nathan Elliott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11947000Abstract: Systems, methods, and computer-readable media are described for compact radar systems. In some examples, a compact radar system can include a first set of transmit antennas, a second set of receive antennas, one or more processors, and at least one computer-readable storage medium storing computer-executable instructions which, when executed by the one or more processors, cause the radar system to coordinate digital beam steering of the first set of transmit antennas and the second set of receive antennas, and coordinate digital beam forming with one or more of the second set of receive antennas to detect one or more objects within a distance of the radar system.Type: GrantFiled: June 6, 2022Date of Patent: April 2, 2024Assignee: FORTEM TECHNOLOGIES, INC.Inventors: Adam Eugene Robertson, Jon Erik Knabenschuh, Lyman Davies Horne, Tyler Drue Park, Matthew Robertson Morin, James David Mackie, Matthew Elliott Argyle, Bryan Alan Davis, Chester Parker Ferry, Daniel Glen Bezzant, Justin Craig Huntington, Nathan James Packard
-
Patent number: 11938295Abstract: Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and/or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition in a subject in need thereof.Type: GrantFiled: September 15, 2022Date of Patent: March 26, 2024Assignee: Biora Therapeutics, Inc.Inventors: Jeffrey A. Shimizu, Mitchell Lawrence Jones, Mark Sasha Drlik, Iman Niknia, Nathan John Muller, Tuyen Nguyen, Christopher Loren Wahl, Edward Mudge, Nicholas Mark Salt, Nia Eleri Stevens, Stuart Robert Abercrombie, Christopher Ian Bunce, Ryan Elliott Jones, Kevin Howe, Pejman Rahimian, Nelson Quintana
-
Patent number: 11857855Abstract: The present invention relates to a method for characterizing a racket head of a ball game racket frame as well as to the representation of a racket head.Type: GrantFiled: July 16, 2021Date of Patent: January 2, 2024Assignee: Head Technology GmbHInventors: Harald Rosenkranz, Nathan Elliott, Stefan Mohr, Ralf Schwenger
-
Patent number: 11732038Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an aldehyde group obtained from oxidation of a 2-hydroxyethylamine moiety on the CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.Type: GrantFiled: February 12, 2021Date of Patent: August 22, 2023Assignee: IMMUNOGEN, INC.Inventors: Nathan Elliott Fishkin, Daniel J. Tavares, Lingyun Rui, Luke B. Harris, Manami Shizuka, Michael Louis Miller, Ravi V. J. Chari
-
Patent number: 11521367Abstract: The present invention relates to a method for characterizing a string pattern of a ball game racket frame as well as to the representation of a string pattern image of a strung ball game racket frame.Type: GrantFiled: July 16, 2021Date of Patent: December 6, 2022Assignee: Head Technology GmbHInventors: Nathan Elliott, Ralf Schwenger
-
Patent number: 11505617Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: GrantFiled: January 7, 2021Date of Patent: November 22, 2022Assignee: IMMUNOGEN, INC.Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V. J. Chari
-
Publication number: 20220019705Abstract: The present invention relates to a method for characterizing the deformation properties of a string pattern of a ball game racket frame as well as to the representation of a string pattern image of a strung ball game racket frame.Type: ApplicationFiled: July 16, 2021Publication date: January 20, 2022Applicant: Head Technology GmbHInventors: Stefan MOHR, Daniel LAU, Nathan ELLIOTT
-
Publication number: 20220019831Abstract: The present invention relates to a method for characterizing a string pattern of a ball game racket frame as well as to the representation of a string pattern image of a strung ball game racket frame.Type: ApplicationFiled: July 16, 2021Publication date: January 20, 2022Applicant: Head Technology GmbHInventors: Nathan ELLIOTT, Ralf SCHWENGER
-
Publication number: 20220016503Abstract: The present invention relates to a method for characterizing a racket head of a ball game racket frame as well as to the representation of a racket head.Type: ApplicationFiled: July 16, 2021Publication date: January 20, 2022Applicant: Head Technology GmbHInventors: Harald ROSENKRANZ, Nathan Elliott, Stefan Mohr, Ralf Schwenger
-
Publication number: 20210299271Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an aldehyde group obtained from oxidation of a 2-hydroxyethylamine moiety on the CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.Type: ApplicationFiled: February 12, 2021Publication date: September 30, 2021Inventors: Nathan Elliott Fishkin, Daniel J. Tavares, Lingyun Rui, Luke B. Harris, Manami Shizuka, Michael Louis Miller, Ravi V.J. Chari
-
Publication number: 20210238301Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: ApplicationFiled: January 7, 2021Publication date: August 5, 2021Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V.J. Chari
-
Patent number: 11006788Abstract: A product dispenser for the dispensing of a product which will show active visual content to proximate viewers. A visual display module is attached to a user-facing surface of the dispenser cover of a product dispenser, to display active visual content to viewers. The active visual content displayed on the active media surface of the dispenser cover could take many forms including changing electronic displays or a translucent surface which can be optionally illuminated or emphasized based on a controller and power source. The product dispenser can be supplied with the visual display module in place on the dispenser cover, or an OEM product dispenser with an insert blank in place on the dispenser cover could also be sold into which the visual display module could be later installed. A media-ready dispenser cover which could be used to retrofit an existing product dispenser with the ability to receive a visual display module is also disclosed.Type: GrantFiled: November 11, 2016Date of Patent: May 18, 2021Inventors: Trevor Thomas, Paul Drouin, Nathan Elliott, Dwayne Melcher
-
Patent number: 10988531Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an aldehyde group obtained from oxidation of a 2-hydroxyethylamine moiety on the CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.Type: GrantFiled: September 2, 2015Date of Patent: April 27, 2021Assignee: IMMUNOGEN, INC.Inventors: Nathan Elliott Fishkin, Daniel Tavares, Lingyun Rui, Luke B. Harris, Manami Shizuka, Michael Louis Miller, Ravi V. J. Chari
-
Patent number: 10947315Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: GrantFiled: December 21, 2018Date of Patent: March 16, 2021Assignee: IMMUNOGEN, INC.Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V. J. Chari
-
Patent number: 10570212Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.Type: GrantFiled: November 30, 2018Date of Patent: February 25, 2020Assignee: IMMUNOGEN, INC.Inventors: Wei Li, Michael Louis Miller, Nathan Elliott Fishkin, Ravi V. J. Chari
-
Publication number: 20190276552Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: ApplicationFiled: December 21, 2018Publication date: September 12, 2019Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V.J. Chari
-
Publication number: 20190263924Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.Type: ApplicationFiled: November 30, 2018Publication date: August 29, 2019Inventors: Wei Li, Michael Louis Miller, Nathan Elliott Fishkin, Ravi V.J. Chari
-
Patent number: 10364294Abstract: The present invention is directed to methods of preparing a conjugate of a cell-binding agent and a drug (such as a cytotoxic compound). The methods comprise the use of an imine reactive compound to enable efficient conjugations of cytotoxic compounds with cell binding agents.Type: GrantFiled: August 15, 2017Date of Patent: July 30, 2019Assignee: IMMUNOGEN, INC.Inventors: Nathan Elliott Fishkin, Michael Louis Miller, Wei Li, Rajeeva Singh
-
Patent number: 10208127Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: GrantFiled: May 8, 2018Date of Patent: February 19, 2019Assignee: IMMUNOGEN, INC.Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V. J. Chari
-
Patent number: RE49918Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.Type: GrantFiled: May 10, 2021Date of Patent: April 16, 2024Assignee: IMMUNOGEN, INC.Inventors: Wei Li, Michael Louis Miller, Nathan Elliott Fishkin, Ravi V. J. Chari